Economy/Home · Economy

Alteogen's Stock Direction on the 9th in Focus... Novartis Deal Worth 4.4165 Trillion Won Reassessed

Investors' attention is focused on the direction of Alteogen's stock price on the 9th. After falling more than 3% the previous day, the value of the multi-trillion-won technology transfer contract signed with Novartis is emerging once again as an investment point. ■ Closed Down 3.15% the Previous D

Wooil Shim
Staff Reporter
6 min read
Alteogen's Stock Direction on the 9th in Focus... Novartis Deal Worth 4.4165 Trillion Won Reassessed
CBC News

Investors' attention is focused on the direction of Alteogen's stock price on the 9th. After falling more than 3% the previous day, the value of the multi-trillion-won technology transfer contract signed with Novartis is emerging once again as an investment point.

■ Closed Down 3.15% the Previous Day... Trading Volume of 657,576 Shares

On the 8th, Alteogen finished trading at 277,000 won, down 9,000 won (3.15%) from the previous trading day. That day, the opening price was 287,500 won, the high was 287,500 won, the low was 277,000 won, and the trading volume was 657,576 shares.

■ Hana Securities: "Contract with Novartis Worth 4.4165 Trillion Won... Estimated to Cover About 10-11 Products"

Ahead of the opening of the domestic stock market on the 9th, market attention is focused on a recent analysis by Hana Securities of the Novartis technology transfer contract.

In a report on the 2nd, Hana Securities analyzed that Alteogen signed a technology transfer contract with Novartis totaling US$3.233 billion, or about 4.4165 trillion won, including upfront payment and milestones. Royalties are separate.

Hana Securities estimated that, given that Alteogen's recent contracts were valued at US$285 million to US$365 million per product, this contract is likely structured to cover about 10-11 products. It analyzed that the per-product value of this contract is around US$294 million to US$322 million, likely including a US$20 million option exercise fee.

■ Significance of Platform Technology Expansion vs. Phased Revenue Recognition

If the contract covers multiple products, it is evaluated as highly significant, since unlike a technology transfer limited to a single drug, Alteogen's platform technology can be extended to multiple pipelines.

However, the total contract amount is not recognized as revenue all at once. The timing and scale of milestone inflows may vary depending on whether conditions at each development, approval, and commercialization stage are met in the future.

Accordingly, the key points to watch in the stock price on the 9th will be whether rebound buying follows the previous day's decline and how the mid- to long-term value of the technology transfer contract is assessed.

[This article was written with the assistance of AI and was composed based on publicly available stock price information and a securities firm report provided by users. The securities firm's content regarding the contract structure and number of products includes estimates, and actual contract terms and future milestone receipt amounts may differ. This article is not investment advice intended to recommend the purchase or sale of any particular stock, and investment decisions and the responsibility arising from them rest with the investor.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.